Data base analyses have revealed that Dysferlin is slightly downregulated in various cancer entities compared to their normal counterparts, including inter alia bladder urothelial carcinoma, breast invasive carcinoma, cervical carcinoma, cholangiocarcinoma, and colon and colorectal carcinoma, with OSCCs not incorporated in this search [11]. This evidence concerns the gene DYSF and bladder transitional cell carcinoma.